patients presenting within four hours of the onset of acute myocardial infarction were randomly assigned to receive 80 to 100 mg of recombinant human-tissue plasminogen activator ( t-pa ) intravenously over a period of three hours ( n = 72 ) or placebo ( n = 66 ) .
C0027051
myocardial
C0032143
recombinant